InsiderTrades.com logo
Claim Your Complimentary Bitcoin Reward
From Crypto Swap Profits   |   Ad
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Secure Your Spot Now
Christopher Paul Simms net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Christopher Simms Biography and Net Worth

SVP of IVERIC bio
Chris Simms is Senior Vice President and Chief Commercial Officer of Iveric Bio. Mr. Simms is an accomplished healthcare leader with more than 20 years of diverse commercial leadership experience at Johnson & Johnson, Genentech, and Novartis, including focused experience in retina, ophthalmology, and optometry. Most recently, he was the Vice President and Head of the Novartis US Ophthalmics business unit which includes the brands BEOVU® and Xiidra®. He joined Novartis in 2017 to build the commercial launch strategy for BEOVU® after leading commercial efforts on Lucentis® at Genentech. Prior to Genentech, he spent 16 years at Johnson & Johnson working with leading brands across their vision care, diabetes and consumer goods businesses in Canada, Japan, and the US. Mr. Simms has a Bachelor of Commerce from Memorial University of Newfoundland and an MBA from York University, Toronto, Canada.

What is Christopher Paul Simms' net worth?

The estimated net worth of Christopher Paul Simms is at least $1.30 million as of January 3rd, 2023. Mr. Simms owns 32,429 shares of IVERIC bio stock worth more than $1,295,539 as of May 8th. This net worth approximation does not reflect any other investments that Mr. Simms may own. Additionally, Mr. Simms receives an annual salary of $715,010.00 as SVP at IVERIC bio. Learn More about Christopher Paul Simms' net worth.

How old is Christopher Paul Simms?

Mr. Simms is currently 48 years old. There are 4 older executives and no younger executives at IVERIC bio. The oldest executive at IVERIC bio is Mr. Glenn P. Sblendorio M.B.A., CEO & Director, who is 67 years old. Learn More on Christopher Paul Simms' age.

What is Christopher Paul Simms' salary?

As the SVP of IVERIC bio, Inc., Mr. Simms earns $715,010.00 per year. There are 3 executives that earn more than Mr. Simms. The highest earning executive at IVERIC bio is Mr. Glenn P. Sblendorio M.B.A., CEO & Director, who commands a salary of $1,360,000.00 per year. Learn More on Christopher Paul Simms' salary.

How do I contact Christopher Paul Simms?

The corporate mailing address for Mr. Simms and other IVERIC bio executives is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. IVERIC bio can also be reached via phone at (609) 474-6755 and via email at [email protected]. Learn More on Christopher Paul Simms' contact information.

Has Christopher Paul Simms been buying or selling shares of IVERIC bio?

Christopher Paul Simms has not been actively trading shares of IVERIC bio during the last quarter. Most recently, Christopher Paul Simms sold 2,368 shares of the business's stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $20.06, for a transaction totalling $47,502.08. Following the completion of the sale, the senior vice president now directly owns 32,429 shares of the company's stock, valued at $650,525.74. Learn More on Christopher Paul Simms' trading history.

Who are IVERIC bio's active insiders?

IVERIC bio's insider roster includes David Carroll (CFO), Pravin Dugel (EVP), Anthony Gibney (EVP), Calvin Roberts (Director), Glenn Sblendorio (CEO), Christopher Simms (SVP), and Keith Westby (COO). Learn More on IVERIC bio's active insiders.

Are insiders buying or selling shares of IVERIC bio?

During the last year, insiders at the sold shares 2 times. They sold a total of 40,000 shares worth more than $1,546,400.00. The most recent insider tranaction occured on July, 3rd when COO Keith Westby sold 20,000 shares worth more than $789,000.00. Insiders at IVERIC bio own 2.7% of the company. Learn More about insider trades at IVERIC bio.

Information on this page was last updated on 7/3/2023.

Christopher Paul Simms Insider Trading History at IVERIC bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/3/2023Sell2,368$20.06$47,502.0832,429View SEC Filing Icon  
8/3/2022Sell12,272$11.25$138,060.0028,547View SEC Filing Icon  
11/18/2021Buy3,069$16.30$50,024.70View SEC Filing Icon  
See Full Table

Christopher Paul Simms Buying and Selling Activity at IVERIC bio

This chart shows Christopher Paul Simms's buying and selling at IVERIC bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IVERIC bio Company Overview

IVERIC bio logo
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.
Read More

Today's Range

Now: $39.95
Low: $39.95
High: $39.95

50 Day Range

MA: $38.88
Low: $36.90
High: $39.95

2 Week Range

Now: $39.95
Low: $9.39
High: $39.99

Volume

N/A

Average Volume

3,616,141 shs

Market Capitalization

$5.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06
Claim Your Complimentary Bitcoin Reward
From Crypto Swap Profits   |   Ad
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Secure Your Spot Now